Showing 7961-7970 of 9898 results for "".
- AbbVie: Rinvoq Hits AD Treat-to-Target Aims as Early as Week 2https://practicaldermatology.com/news/abbvie-rinvoq-hits-ad-treat-to-target-aims-as-early-as-week-2/2461142/Treatment with Rinvoq® (upadacitinib) 15mg or 30mg allows patients to rapidly achieve their initial three-month acceptable treatment target goal at Week 2, with consistent achievement through Week 16, results of a new analysis show. Using the framework of the recently developed evidence-based
- Dupixent Performs Well in Phase 3s for Prurigo Nodularishttps://practicaldermatology.com/news/dupixent-performs-well-in-phase-3s-for-prurigo-nodularis/2461138/Detailed positive results from the Phase 3 PRIME2 trial show Dupixent® (dupilumab) significantly reduced itch and skin lesions compared to placebo in adults with uncontrolled prurigo nodularis. Findings were presented in a late-breaking session at the American Academy of Dermat
- DefenAge Receives Two US Patents For Melasma and Hair Growthhttps://practicaldermatology.com/news/defenage-receives-two-us-patents-for-melasma-and-hair-growth/2461118/The US Patent and Trademark Office has granted two new patents to Defanage Skincare for the use of Defensin-molecules for topical treatment of hair loss in skin affected by alopecia and of the hyperpigmented lesions of melasma: &l
- Residents of Distinction Recognized at Maui Dermhttps://practicaldermatology.com/news/residents-of-distinction-honored-at-maui-derm/2461111/Sydney Liang, MD, a second-year resident at New York University, was awarded the Overall Grand Prize and was one of five dermatology residents recognized by DermMentors™ as part of the 11th Annual dermMentors™ Resident of Distinction Award™ for 2022.
- Novan, Inc. Acquires EPI Healthhttps://practicaldermatology.com/news/novan-inc-acquires-epi-health/2461106/EPI Health is now a Novan Company. The EP Group today announced the acquisition of EPI Health, LLC by Novan, Inc. EPI Health is a leading company in the US dermatology sector with an established sales force and commercial team with existing, deep market relationships across the de
- Vial Welcomes David Pariser, MD to its Boardhttps://practicaldermatology.com/news/vial-welcomes-david-pariser-md-to-its-board/2461105/David Pariser, MD has joined the Vial Scientific Advisory Board. The Senior Physician at Pariser Dermatology Specialists, Dr. Pariser will share the Vial CRO team and sponsors his knowledge and insights from more than 40 years as a practicing dermatologist. The
- Nancy Beesley Joins Dermavant Board of Directorshttps://practicaldermatology.com/news/nancy-beesley-joins-dermavant-board-of-directors/2461101/Nancy Beesley has been appointed to Dermavant Sciences’ Board of Directors. She joins Dermavant with more than 25 years of experience in commercializing and branding therapeutics for the treatment of various dermatological, ophthalmic, and neurologica
- Differin Doubles Down on Retinoid Education Week with New Campaign Launchhttps://practicaldermatology.com/news/differin-doubles-down-on-retinoid-education-week-with-new-campaign-launch/2461100/Differin Gel is launching a digital and audio marketing campaign that will culminate in a strategic partnership with Acast Creative and the
- Aquaphor Unveils New Purpose-Driven Brand Campaignhttps://practicaldermatology.com/news/aquaphor-unveils-new-purpose-driven-brand-campaign/2461099/Aquaphor is launching its first-ever brand purpose campaign, "Before & Aquaphor." Inspired by the growing field of psychodermatology, this new integrated campaign highlights the connection between our skin health and our emotional well-being.
- Butt First, Endo Launches New Qwo Consumer Campaignhttps://practicaldermatology.com/news/butt-first-endo-launches-new-qwo-consumer-campaign/2461095/Endo International plc is kicking off more than 200 patient events across the United States as part of Butt First, a new direct-to-consumer awareness campaign about Qwo (collagenase clostridium histolyticum-aaes). Qwo received FDA approval in Jul